APPROVED BY OMB: NO. 3150-0120 EXPIRES: 01/31/2023



AUTHORIZED USER TRAINING, EXPERIENCE, AND PRECEPTOR ATTESTATION

(for uses defined under 35.300) [10 CFR 35.57, 35.390, 35.392, 35.394, and 35.396]

Name of Proposed Authorized User					State or Territory Where Licensed				
Reque	ested Au	thorizatior	n(s) <i>(check all tha</i>	at apply):					
	35.300 Use of unsealed byproduct material for which a written directive is required								
OF	OR								
	35.300	35.300 Oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)							
	35.300	35.300 Oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)							
	35.300 Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.								
PART I TRAINING AND EXPERIENCE (Select one of the three methods below)									
* Training and Experience, including board certification, must have been obtained within the 7 years preceding the date of application or the individual must have related continuing education and experience since the required training and experience was completed. Provide dates, duration, and description of continuing education and experience related to the uses checked above.									
1 .	Board	Certificat	tion_						
а	. Provid	е а сору с	of the board certif	fication.					
b		•	vide documentation vperience.	on on supervised o	ase experience. ⁻	Γhe table in section 3.c. may be used to			
С	superv	For 35. 396 , provide documentation on classroom and laboratory training, supervised work experience, and supervised clinical case experience. The tables in sections 3.a., 3.b., and 3.c. may be used to document this experience. Skip to and complete Part II Preceptor Attestation.							
d	For a board certification issued on or before October 24, 2005 that is listed in 10 CFR 35.57(b)(2)(ii), provide the following:								
	(i) D	(i) Documentation that the individual performed each use checked above on or before October 24, 2005.							
	(ii) Dates, duration, and description of continuing education and experience within the past seven years for each use checked above.								
е	. Stop h	ere.							
2 .	Currer	nt 35.300,	35.400, or 35.60	0 Authorized Use	r Seeking Additio	onal Authorization			
a.	a. Authorized User on Materials License under the requirements below or								
	equiva	equivalent Agreement State requirements (check all that apply):							
	<u> </u>	.390	35.392	35.394	35.490	35.690			
b.	superv certifie	ised case	experience. The a copy of the ce	table in section 3.	c. may be used to	de documentation on additional required document this experience. If board ertified then provide completed Part II			

(01-2020)

AUTHORIZED USER TRAINING, EXPERIENCE, AND PRECEPTOR ATTESTATION (for uses defined under 35.300) [10 CFR 35.57, 35.390, 35.392, 35.394, and 35.396] (continued)

c. If currently authorized under 35.490 or 35.690 and requesting authorization for 35.396, provide documentation on classroom and laboratory training, supervised work experience, and supervised clinical case experience. The tables in sections 3.a., 3.b., and 3.c. may be used to document this experience. Also provide completed Part II Preceptor Attestation. 3. Training and Experience for Proposed Authorized User 35.390 a. Classroom and Laboratory Training 35.392 35.394 35.396 Clock Dates of Description of Training Location of Training Hours Training* Radiation physics and instrumentation Radiation protection Mathematics pertaining to the use and measurement of radioactivity Chemistry of byproduct material for medical use Radiation biology **Total Hours of Training:** b. Supervised Work Experience 35.390 35.392 35.394 35.396 (If more than one supervising individual is necessary to document supervised training, provide multiple copies of this page.) Supervised Work Experience Total Hours of Experience: Description of Experience Location of Experience/License or Dates of Confirm Permit Number of Facility Must Include: Experience* Ordering, receiving, and Yes unpacking radioactive materials safely and performing the No related radiation surveys Performing quality control procedures on instruments Yes used to determine the activity of dosages and performing No checks for proper operation of survey meters Calculating, measuring, and Yes safely preparing patient or human research subject No dosages Using administrative controls to Yes prevent a medical event involving the use of unsealed No byproduct material Using procedures to contain Yes spilled byproduct material safely and using proper No decontamination procedures

Training and Experience for Supervised Work Experience					
Supervising Individual		License/Permit Number listing supervising individual as an authorized user			
Supervising individual meets th	e requirements below,	or equivalent Agreement State requirements			
☐ 35.392 ☐ Oral Nal-13 gigabecque ☐ 35.394 ☐ Oral Nal-13 ☐ Parenteral a used for its	administering dosages of: requiring a written directive in quantities less than or equal to 1.22 ls (33 millicuries) in quantities greater than 1.22 gigabecquerels (33 millicuries) ministration of any radioactive drug that contains a radionuclide that is prima ectron emission, beta radiation characteristics, alpha radiation characteristic ergy of less than 150 keV, for which a written directive is required.				
** Supervising Authorized User must I individual requesting authorized use		ering dosages in the same dosage category or categories	as the		
c. Supervised Clinical Case Ex If more than one supervising indivi this page.	•	ment supervised work experience, provide multiple	copies of		
Description of Experience	Number of Cases Involving Personal Participation	Location of Experience/License or Permit Number of Facility	Dates of Experience*		
Oral administration of sodium fodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)	3				
Oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)					
Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.					

3. Training and Experience for Proposed Authorized User (continued)							
c. Supervised Clinical Case Experience (continued)							
Supervising Individual	License/Permit Number listing supervising individual as an authorized user						
Supervising individual meets the requirements below, or equiva-	alent Agreement State requirements (check all that apply)**:						
35.390 With experience administering dosages of							
35.392 Oral Nal-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)							
35.394 Oral Nal-131 in quantities greater than	n 1.22 gigabecquerels (33 millicuries)						
☐ 35.396 ☐ Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.							
** Supervising Authorized User must have experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status.							
d. Provide completed Part II Preceptor Attestation.							
	PTOR ATTESTATION						
Note: This part must be completed by the individual's preceptor. The preceptor does not have to be the supervising individual as long as the preceptor provides, directs, or verifies training and experience required. If more than one preceptor is necessary to document experience, obtain a separate preceptor statement from each.							
By checking the boxes below, the preceptor is not	attesting to the individual's "general clinical competency."						
First Section Check one of the following for the requested authorization:							
For 35.390:							
I attest that	has satisfactorily completed the 700 hours of training						
Name of Proposed Authorized User	_						
and experience, including a minimum of 200 hours of classroom and laboratory training, as required by 10 CFR 35.390 (b)(1).							
For 35.392:							
I attest that Name of Proposed Authorized User	has satisfactorily completed the 80 hours of classroom						
and laboratory training, as required by 10 CFR 35.392(c)(1), and the supervised work and clinical case experience required in 35.392(c)(2).							
For 35.394:							
☐ I attest that	has satisfactorily completed the 80 hours of classroom						
Name of Proposed Authorized User							
and laboratory training, as required by 10 CFR 35.394 (c)(1), and the supervised work and clinical case experience required in 35.394(c)(2).							

Second Section								
I attest that	has satisfactorily completed the required clinical case							
Name of Proposed Authorized User								
experience required in 35.390(b)(1)(ii)G listed below:								
	 Oral Nal-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries) 							
Oral Nal-131	Oral Nal-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)							
used for its ele	Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.							
Third Section								
I attest that	is able to independently fulfill the radiation safety-related							
	Name of Proposed Authorized User							
duties as an auth	orized user for the medical uses authorized under 10 CFR 35.300 for:							
	-131 requiring a written directive in quantities less than or equal to 1.22 querels (33 millicuries)							
Oral Nal-131	al-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)							
Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.								
Fourth Section								
For 35.396:								
Current 35.490 o	35.690 authorized user:							
I attest that	is an authorized user under 10 CFR 35.490 or 35.690							
	Name of Proposed Authorized User							
or equivalent Agreement State requirements, has satisfactorily completed the 80 hours of classroom and laboratory training, as required by 10 CFR 35.396 (b)(1), and the supervised work and clinical case experience required by 35.396(b)(2), and is able to independently fulfill the radiation safety-related duties as an authorized user under 10 CFR 35.300 for: Parenteral administration of any radioactive drug that contains a radionuclide that is primarily								
used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.								
OR								
Board Certificati	<u>on:</u>							
☐ I attest that	has satisfactorily completed the board certification							
	Name of Proposed Authorized User							
requirements of 35.396(a)(3), has satisfactorily completed the 80 hours of classroom and laboratory training required by 10 CFR 35.396 (b)(1) and the supervised work and clinical case experience required by 35.396(b)(2), and is able to independently fulfill the radiation safety-related duties as an authorized user under 10 CFR 35.300 for:								

Fifth Section							
Complete one of the following for the attestation and signature:							
Authorized User							
☐ I meet the requirements below, or equivalent Agreement State requirements, as an authorized user for:							
☐ 35.390 ☐ 35.392 ☐ 35.394 ☐ 35.396	35.	57 for 35.300 uses					
I have experience administering dosages in the following categorequesting authorization:	ories for whic	h the proposed Authori	zed User is				
Oral Nal-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)							
Oral Nal-131 in quantities greater than 1.22 gigabecquerels	(33 millicurie	es)					
Parenteral administration of any radioactive drug that contains a radionuclide that is primarily used for its electron emission, beta radiation characteristics, alpha radiation characteristics, or photon energy of less than 150 keV, for which a written directive is required.							
OR							
Residency Program Director:							
I affirm that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements below or equivalent Agreement State requirements:							
35.390 35.392 35.394 35.394	96 🗌 3	5.57 for 35.300 uses					
I affirm that this facility member has experience in administering dosages in the same dosage category or categories for which the individual is requesting authorized user status and concurs with the attestation I am providing as program director.							
I affirm that the residency training program is approved by the:							
Residency Review Committee of the Accreditation Council for Graduate Medical Education							
Royal College of Physicians and Surgeons of Canada							
Council on Post-Graduate Training of the American Osteop	oathic Assoc	iation					
I affirm that the residency training program includes training and experience specified in:							
□ 35.390 □ 35.394 □ 35.396							
Name of Facility	1:/D	ZA Niversia - m					
Name of Facility:	License/Pern	iil Number:					
Name of Preceptor or Residency Program Director (Typed or Printed)		Telephone Number	Date				
Signature							